Generics BulletinStada has credited its Alvotech-partnered Uzpruvo (ustekinumab) European biosimilar rival to Stelara for driving up its sales in the first quarter of 2025. The German giant’s Specialty division – whic
Generics BulletinIf Stada is indeed set to announce an initial public offering in the coming days, then its latest results have been positioned as a strong enticement to invest in the firm, which says it is outperform
Generics BulletinWhen Stada’s head of western Europe and Germany, Stephan Eder, was recently named as the new president of industry association Medicines for Europe, he set out his three key priorities as ensuring s
Generics BulletinGerman industry giant Stada has made its strongest indication yet that an initial public offering could be in the cards, following months of rumors that a change in ownership could be imminent. The fi